美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Portfolio Building Block World Pharma and Biotech Index ETF

28.37

-0.1233-0.43%

盤後：28.400.0278+0.10%19:30 EDT

成交量：11.44萬

成交額：324.57萬

市值：10.30億

市盈率：- -

高：28.43

開：28.43

低：28.28

收：28.50

52周最高：29.90

52周最低：24.24

股本：3,631.00萬

流通股本：3,631.00萬

量比：1.41

換手率：0.32%

股息：0.02

股息率：0.08%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

實控人將離職、業績補償條款存設計缺陷，瑞豐高材併購交易惹爭議

通用電氣可再生能源表示，有意開展更多併購交易，且幾乎可以肯定交易將圍繞自身核心業務展開。

阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。

118款生物藥專利懸崖將至，中國藥企業迎戰MNC最大專利懸崖

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/PBPH"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"PBPH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBPH\",,,,,undefined,":{"symbol":"PBPH","market":"US","secType":"STK","nameCN":"Portfolio Building Block World Pharma and Biotech Index ETF","latestPrice":28.3722,"timestamp":1789761600000,"preClose":28.4955,"halted":0,"volume":114433,"hourTrading":{"tag":"盘后","latestPrice":28.4,"preClose":28.3722,"latestTime":"19:30 EDT","volume":7,"amount":198.6054,"timestamp":1789774205434,"change":0.0278,"changeRate":0.00098,"amplitude":0},"delay":0,"changeRate":-0.004326998999842095,"floatShares":36310000,"shares":36310000,"eps":0,"marketStatus":"休市中","change":-0.1233,"latestTime":"09-18 16:00:00 EDT","open":28.43,"high":28.43,"low":28.2823,"amount":3245742.13777,"amplitude":0.005183,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":28.4955,"nav":28.433261,"aum":1032411706.91,"dividendRate":0.000807,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":28.4,"preClose":28.3722,"latestTime":"19:30 EDT","volume":7,"amount":198.6054,"timestamp":1789774205434,"change":0.0278,"changeRate":0.00098,"amplitude":0},"volumeRatio":1.4131019980509474},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBPH\",,,,,undefined,":{"symbol":"PBPH","floatShares":36310000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.4131019980509474,"shares":36310000,"dividePrice":0.022885,"high":28.43,"amplitude":0.005183,"preClose":28.4955,"low":28.2823,"week52Low":24.241,"pbRate":"--","week52High":29.9,"institutionHeld":0,"latestPrice":28.3722,"eps":0,"divideRate":0.000807,"volume":114433,"delay":0,"ttmEps":0,"open":28.43,"prevYearClose":25.2428,"prevWeekClose":27.8041,"prevMonthClose":28.6563,"prevQuarterClose":27.177,"fiveDayClose":27.8041,"twentyDayClose":29.2122,"sixtyDayClose":26.0991},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBPH\",params:#limit:5,,,undefined,":[{"date":"2025-12-24","symbol":"PBPH","amount":0.022885,"announcedDate":"2025-12-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-24","defaultRemindTime":1766586600000,"name":"Portfolio Building Block World Pharma and Biotech Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-24","currency":"USD","dateTimestamp":1766552400000,"payDate":"2025-12-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBPH\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-24","recordDate":"2025-12-24","paymentDate":"2025-12-26","value":0.022885,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBPH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PBPH\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668836871","title":"實控人將離職、業績補償條款存設計缺陷，瑞豐高材併購交易惹爭議","url":"https://stock-news.laohu8.com/highlight/detail?id=2668836871","media":"市场资讯","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668836871?lang=zh_tw&edition=fundamental","pubTime":"2026-09-20 14:30","pubTimestamp":1789885800,"startTime":"0","endTime":"0","summary":"业绩承诺方应连带地向瑞丰高材承担补偿责任，补偿方式可包括现金补偿、股份补偿及瑞丰高材认可的其他方式。业绩补偿条款存多处设计缺陷值得注意的是，此次交易的业绩补偿条款也被认为过于宽松、自相矛盾而约束力不足。第三条业绩补偿条款更接近一个无强制约束力的意向性条款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-20/doc-inisnhay9279485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CANC","PSP","UYG","DFMC","RSPH","ACTV","IEFN","TBXU","IYH","TMED","IBBQ","GTPE","BK0028","MMID","PRVT","BK4588","BK0086","FFSM","BK4585","BK0177","PBPH","BK0229","VXF","XLFI","300243","PEVC","MNA","RFG","AAUM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667984205","title":"通用電氣可再生能源表示，有意開展更多併購交易，且幾乎可以肯定交易將圍繞自身核心業務展開。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667984205","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667984205?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 23:38","pubTimestamp":1789573119,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["UYG","XLFI","RSPH","TMED","VCLN","PWER","PSP","TBXU","ACTV","PEVC","IEFN","MNA","FFSM","IBBQ","PBPH","VXF","SMOG","MMID","PBW","SDGS","SOLR","BK4585","RFG","CANC","IYH","PRVT","RNRG","HEAT","ACES","GTPE","DFMC","AAUM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SBIO","FBT","BIB","AZNH","GNOM","WDNA","BK4588","IBB","RSPH","BK4585","PSCH","HELX","IBRN","BBP","MRNY","PBE","FTXH","IYH","IDNA","BIOY","LU1992135472.HKD","LU2272731865.HKD","PJP","MRNX","LU2272731600.USD","IEIH","LU2322448791.USD","LU2322448957.HKD","XPH","LU2272731782.SGD","XBIX","IE00B5TLWC47.USD","BBH","CANC","SYNB","LU1992135399.USD","TMED","BME","IEHS","LFSC","PBPH","PPH","RXL","LU2473716301.USD","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666563124","title":"118款生物藥專利懸崖將至，中國藥企業迎戰MNC最大專利懸崖","url":"https://stock-news.laohu8.com/highlight/detail?id=2666563124","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666563124?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 15:26","pubTimestamp":1789025185,"startTime":"0","endTime":"0","summary":"BCG合伙人杜菁博士指出，未来几年全球MNC将迎来史上最大专利悬崖，有118种生物制剂将会失去相应的专利保护，涉及2340亿美元市场。然而，目前这118款即将到期分子中，只有极少数在火热开发，大量缺口有待生物类似药填补。目前来说，创新药出海还没办法完成这个闭环，但生物类似药作为先头部队做出海试验，企业风险和获益会更高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789025064363150858","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["JDOC","RSPH","BBP","BBH","BME","GSKH","PJP","TRUH","FXH","TMED","MEDI","APXH","PBPH","FHLC","159839","PPH","IHE","IYH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PBPH\",params:#limit:6,delay:false,,,undefined,":[]}}